News for hackers. Stuff that matters.

A comment on $6.96B was raised by private longevity companies in 2022. Parent comment

Re:$6.96B was raised by private longevity companies in 2022 by ceejayoz on Friday January 27, 2023 @03:19PM (#34551277)
It's a monoclonal antibody.

I suspect it'll look cheap in comparison to life extension treatments.

[ Parent | on HN ]
Re:$6.96B was raised by private longevity companies in 2022 by jjk166 on Friday January 27, 2023 @04:52PM (#34552395)
That's because monoclonal antibodies are targeted to a very specific protein. Polyclonal antibodies which can be used more generally are much cheaper. You're paying for the purity, not the substance.
[ Parent | on HN ]